出版信息
投稿信息
期刊简介
About Journal of Clinical OncologyJCO is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). Published thrice monthly, JCO is the foremost peer-reviewed journal focusing on clinical cancer research and the authoritative source for current information on the diagnosis and treatment of patients with cancer.Why publish in Journal of Clinical Oncology?We offer rapid publication, high visibility, and the opportunity to have your research widely read.Speed of publication Average time from submission to first decision is just 10 days. Articles are published online first, weeks ahead of issue publication. A Rapid Communications program that fast-tracks important research.Impact and reach Cited more than 133,000 times in 2014—ranked #1 among all clinical oncology journals.(1) 2014 ISI Impact Factor: 18.443(1) Eigenfactor Rank: #1(1) Google Scholar h5-index Rank: #1(2) Over 6.6 million full-text article request each year. Read by more than 25,000 oncologists in over 120 countries. Accessed by nearly 10,000 academic, corporate, and government institutions worldwide.Benefits of partnering with ASCO Gain instant recognition by publishing with ASCO, the most trusted source in oncology information. Have your article promoted via ASCO publications, websites, and social media. Take advantage of immediate open access options for your manuscript.The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.The acceptance rate for Original Reports is 13%.JCO is published three times per month -- a total of 36 issues per year.JCO provides free, or significantly discounted, online access to public health institutions in more than 100 developing countries through the World Health Organization''''s Health InterNetwork Access to Research Initiative (HINARI). Through HINARI, JCO aims to strengthen public health services by providing public health workers, researchers, and policy makers access to high-quality, relevant, and timely medical information.
关于临床肿瘤学杂志JCO是美国临床肿瘤学会(ASCO)的主要科学论坛。JCO每月出版三次，是最重要的同行评审期刊，专注于临床癌症研究和权威来源的最新信息诊断和治疗癌症患者。为什么要发表在临床肿瘤学杂志上?我们提供快速出版，高能见度，并有机会让您的研究广泛阅读。出版速度从提交到第一次决定的平均时间只有10天。文章首先在网上发表，比发表时间提前几周。快速跟踪重要研究的快速通信程序。影响和达到2014年被引用13.3万余次，在所有临床肿瘤学期刊中排名第一。2014 ISI影响因子:18.443(1)特征因子排名:# 1 (1)谷歌Scholar h5索引排名:#1(2)每年有超过660万篇全文要求。超过120个国家的25000名肿瘤学家阅读了这本书。全球近10,000个学术、企业和政府机构访问。与ASCO合作的好处通过与ASCO，肿瘤学信息中最值得信赖的来源合作，获得即时的认可。通过ASCO出版物、网站和社交媒体来推广你的文章。利用即时开放的选项为您的手稿。临床肿瘤学杂志为其读者提供最可靠、最权威的资源，以传播重要的临床肿瘤学研究。在印刷和电子格式，JCO致力于出版最高质量的文章致力于临床研究。最初的报告仍然是JCO关注的焦点，但是通过适当选择与癌症患者护理相关的社论、评论、评论和其他工作，这种科学交流得到了加强。原始报告的通过率为13%。JCO每月出版三次，每年出版36期。JCO通过世界卫生组织的卫生互联网络研究倡议(HINARI)向100多个发展中国家的公共卫生机构提供免费或大幅折扣的在线访问。通过HINARI, JCO旨在通过向公共卫生工作者、研究人员和决策者提供高质量、相关和及时的医疗信息来加强公共卫生服务。
征稿信息
影响趋势
相关期刊
服务流程
